|
1
|
Busing KA, Schulte-Sasse C, Fluchter S,
Suselbeck T, Haase KK, Neff W, Hirsch JG, Borggrefe M and Duber C:
Cerebral infarction: Incidence and risk factors after diagnostic
and interventional cardiac catheterization-prospective evaluation
at diffusion-weighted MR imaging. Radiology. 235:177–183. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lindley RI, Wardlaw JM, Sandercock PA,
Rimdusid P, Lewis SC, Signorini DF and Ricci S: Frequency and risk
factors for spontaneous hemorrhagic transformation of cerebral
infarction. J Stroke Cerebrovasc Dis. 13:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hosomi N, Sueda Y, Masugata H, Dobashi H,
Murao K, Ueno M, Miki T, Kohno M, Nishiyama A and Matsumoto M: The
optimal timing of antihypertensive medication administration for
morning hypertension in patients with cerebral infarction.
Hypertens Res. 35:720–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fukuta T, Asai T, Sato A, Namba M,
Yanagida Y, Kikuchi T, Koide H, Shimizu K and Oku N:
Neuroprotection against cerebral ischemia/reperfusion injury by
intravenous administration of liposomal fasudil. Int J Pharm.
506:129–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang C, Tao W, Liu M and Wang D: Efficacy
and safety of human urinary kallidinogenase injection for acute
ischemic stroke: A systematic review. J Evid Based Med. 5:31–39.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Subramaniam S and Hill MD: Massive
cerebral infarction. Neurologist. 11:150–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Camerlingo M, Valente L, Tognozzi M,
Beretta GL, Moschini L and Cesana BM: C-reactive protein levels in
the first three hours after acute cerebral infarction. Int J
Neurosci. 121:65–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee BJ, Egi Y, van Leyen K, Lo EH and Arai
K: Edaravone, a free radical scavenger, protects components of the
neurovascular unit against oxidative stress in vitro. Brain Res.
1307:22–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang PL, Wang YX, Chen Y, Zhang CH, Li
CH, Dong Z, Yin H, Zhang FF and Wang JH: Use of intravenous
thrombolytic therapy in acute ischemic stroke patients: Evaluation
of clinical outcomes. Cell Biochem Biophys. 72:11–17. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiao L, Zhang J, Li Z, Liu H, Chen Y and
Xu S: Edaravone alleviates delayed neuronal death and long-dated
cognitive dysfunction of hippocampus after transient focal ischemia
in Wistar rat brains. Neuroscience. 182:177–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Isahaya K, Yamada K, Yamatoku M, Sakurai
K, Takaishi S, Kato B, Hirayama T and Hasegawa Y: Effects of
edaravone, a free radical scavenger, on serum levels of
inflammatory biomarkers in acute brain infarction. J Stroke
Cerebrovasc Dis. 21:102–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang G and Xu W: Edaravone may be an
efficacious adjunctive therapeutic agent for decompression
sickness: An editorial perspective. Undersea Hyperb Med.
40:215–217. 2013.PubMed/NCBI
|
|
13
|
Ahmad A, Khan MM, Javed H, Raza SS, Ishrat
T, Khan MB, Safhi MM and Islam F: Edaravone ameliorates oxidative
stress associated cholinergic dysfunction and limits apoptotic
response following focal cerebral ischemia in rat. Mol Cell
Biochem. 367:215–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakase T, Yoshioka S and Suzuki A: Free
radical scavenger, edaravone, reduces the lesion size of lacunar
infarction in human brain ischemic stroke. BMC Neurol. 11:392011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kikuchi K, Tancharoen S, Takeshige N,
Yoshitomi M, Morioka M, Murai Y and Tanaka E: The efficacy of
edaravone (radicut), a free radical scavenger, for cardiovascular
disease. Int J Mol Sci. 14:13909–13930. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu XY, Yao LL, Chen YJ, Tao BB, Yu YC,
Bian WH, Yu J and Wang YG: Survivin is involved in the
anti-apoptotic effect of edaravone in PC12 cells. Mol Cell Biochem.
327:21–28. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan Y, Gong K, Ma T, Zhang L, Zhao N,
Zhang X, Tang P and Gong Y: Protective effect of edaravone against
Alzheimer's disease-relevant insults in neuroblastoma N2a cells.
Neurosci Lett. 531:160–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura K, Aoki J, Sakamoto Y, Kobayashi K,
Sakai K, Inoue T, Iguchi Y and Shibazaki K: Administration of
edaravone, a free radical scavenger, during t-PA infusion can
enhance early recanalization in acute stroke patients - a
preliminary study. J Neurol Sci. 313:132–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jian Z, Yong R, Chengliang Z, Yu S and
Chen WH: Preparation and physicochemical characteristics of the
complex of edaravone with hydroxypropyl-β-cyclodextrin. Carbohydr
Polym. 83:1101–1105. 2011. View Article : Google Scholar
|
|
20
|
Oster S, Radad K, Scheller D, Hesse M,
Balanzew W, Reichmann H and Gille G: Rotigotine protects against
glutamate toxicity in primary dopaminergic cell culture. Eur J
Pharmacol. 724:31–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
